113 related articles for article (PubMed ID: 23562062)
1. Arylsulfonamide pyrimidines as VLA-4 antagonists.
Xu YZ; Konradi AW; Bard F; Dappen M; Dofiles L; Dreyer M; Gallager I; Garrido C; Krimm M; Liao Z; Messersmith E; Mutter L; Pleiss MA; Samant B; Semko CM; Smith J; Stappenbeck F; Stupi B; Vandervert C; Welch B; Wipke B; Yednock T
Bioorg Med Chem Lett; 2013 May; 23(10):3070-4. PubMed ID: 23562062
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
[TBL] [Abstract][Full Text] [Related]
3. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists.
Huryn DM; Konradi AW; Ashwell S; Freedman SB; Lombardo LJ; Pleiss MA; Thorsett ED; Yednock T; Kennedy JD
Curr Top Med Chem; 2004; 4(14):1473-84. PubMed ID: 15544538
[TBL] [Abstract][Full Text] [Related]
4. Sulphonamide-based small molecule VLA-4 antagonists.
Stasiak M; Mehlin C; Boni E; Vaisar T; Little T; Kim HO; Qabar M
Bioorg Med Chem Lett; 2003 Nov; 13(21):3875-8. PubMed ID: 14552799
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.
Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB
Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179
[TBL] [Abstract][Full Text] [Related]
6. N-Tetrahydrofuroyl-(L)-phenylalanine derivatives as potent VLA-4 antagonists.
Yang GX; Chang LL; Truong Q; Doherty GA; Magriotis PA; de Laszlo SE; Li B; MacCoss M; Kidambi U; Egger LA; McCauley E; Van Riper G; Mumford RA; Schmidt JA; Hagmann WK
Bioorg Med Chem Lett; 2002 Jun; 12(11):1497-500. PubMed ID: 12031328
[TBL] [Abstract][Full Text] [Related]
7. 4-(Pyrrolidinyl)methoxybenzoic acid derivatives as a potent, orally active VLA-4 antagonist.
Chiba J; Iimura S; Yoneda Y; Sugimoto Y; Horiuchi T; Muro F; Ochiai Y; Ogasawara T; Tsubokawa M; Iigou Y; Takayama G; Taira T; Takata Y; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1515-29. PubMed ID: 17077548
[TBL] [Abstract][Full Text] [Related]
8. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
9. Discovery and SAR of 6-alkyl-2,4-diaminopyrimidines as histamine H₄ receptor antagonists.
Savall BM; Chavez F; Tays K; Dunford PJ; Cowden JM; Hack MD; Wolin RL; Thurmond RL; Edwards JP
J Med Chem; 2014 Mar; 57(6):2429-39. PubMed ID: 24495018
[TBL] [Abstract][Full Text] [Related]
10. Aza-bicyclic amino acid sulfonamides as alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists.
Dyatkin AB; Hoekstra WJ; Kinney WA; Kontoyianni M; Santulli RJ; Kimball ES; Fisher MC; Prouty SM; Abraham WM; de Garavilla L; Andrade-Gordon P; Hlasta DJ; He W; Hornby PJ; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2004 Feb; 14(3):591-6. PubMed ID: 14741249
[TBL] [Abstract][Full Text] [Related]
11. Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists.
Crofts F; Rohatagi S; Pino M; DeLise B; Zhang J; Nguyen M; Guittin P; Barbellion S; Brunel P; Hofmann T; Schmidt J; Wong M; Lockey P; Lerman S; Clark R
Birth Defects Res B Dev Reprod Toxicol; 2004 Apr; 71(2):69-79. PubMed ID: 15098200
[TBL] [Abstract][Full Text] [Related]
12. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor.
Das J; Chen P; Norris D; Padmanabha R; Lin J; Moquin RV; Shen Z; Cook LS; Doweyko AM; Pitt S; Pang S; Shen DR; Fang Q; de Fex HF; McIntyre KW; Shuster DJ; Gillooly KM; Behnia K; Schieven GL; Wityak J; Barrish JC
J Med Chem; 2006 Nov; 49(23):6819-32. PubMed ID: 17154512
[TBL] [Abstract][Full Text] [Related]
13. N-(pyrimidin-4-yl) and N-(pyridin-2-yl) phenylalanine derivatives as VLA-4 integrin antagonists.
Porter JR; Archibald SC; Brown JA; Childs K; Critchley D; Head JC; Hutchinson B; Parton TA; Robinson MK; Shock A; Warrellow GJ; Zomaya A
Bioorg Med Chem Lett; 2002 Jun; 12(12):1595-8. PubMed ID: 12039570
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
[TBL] [Abstract][Full Text] [Related]
15. Amelioration of collagen-induced arthritis in mice by a novel phosphodiesterase 7 and 4 dual inhibitor, YM-393059.
Yamamoto S; Sugahara S; Ikeda K; Shimizu Y
Eur J Pharmacol; 2007 Mar; 559(2-3):219-26. PubMed ID: 17250824
[TBL] [Abstract][Full Text] [Related]
16. Studies on disease-modifying antirheumatic drugs: synthesis of novel quinoline and quinazoline derivatives and their anti-inflammatory effect.
Baba A; Kawamura N; Makino H; Ohta Y; Taketomi S; Sohda T
J Med Chem; 1996 Dec; 39(26):5176-82. PubMed ID: 8978845
[TBL] [Abstract][Full Text] [Related]
17. Imidazopyridines as VLA-4 integrin antagonists.
Phillips DJ; Davenport RJ; Demaude TA; Galleway FP; Jones MW; Knerr L; Perry BG; Ratcliffe AJ
Bioorg Med Chem Lett; 2008 Jul; 18(14):4146-9. PubMed ID: 18539454
[TBL] [Abstract][Full Text] [Related]
18. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data.
Bendele A; McAbee T; Sennello G; Frazier J; Chlipala E; McCabe D
Arthritis Rheum; 1999 Mar; 42(3):498-506. PubMed ID: 10088773
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and pharmacokinetic study of prolyl-1-piperazinylacetic acid and prolyl-4-piperidinylacetic acid derivatives as VLA-4 antagonists.
Chiba J; Takayama G; Takashi T; Yokoyama M; Nakayama A; Baldwin JJ; McDonald E; Moriarty KJ; Sarko CR; Saionz KW; Swanson R; Hussain Z; Wong A; Machinaga N
Bioorg Med Chem; 2006 Apr; 14(8):2725-46. PubMed ID: 16377201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
